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Abstract The extracellular matrix molecule tenascin-C is
highly expressed during embryonic development, tissue
repair and in pathological situations such as chronic inflam-
mation and cancer. Tenascin-C interacts with several other
extracellular matrix molecules and cell-surface receptors,
thus affecting tissue architecture, tissue resilience and cell
responses. Tenascin-C modulates cell migration, proliferation
and cellular signaling through induction of pro-inflammatory
cytokines and oncogenic signaling molecules amongst other
mechanisms. Given the causal role of inflammation in cancer
progression, common mechanisms might be controlled by
tenascin-C during both events. Drugs targeting the expression
or function of tenascin-C or the tenascin-C protein itself are
currently being developed and some drugs have already
reached advanced clinical trials. This generates hope that
increased knowledge about tenascin-C will further improve
managementofdiseaseswithhightenascin-Cexpressionsuch






ACE angiotensin converting enzyme
AT-1 angiotensin II type 1 receptor
bFGF basic fibroblast growth factor
CALEB chicken acidic leucine-rich EGF like domain
containing brain protein
c-Met mesenchymal-epithelial transition factor




EDNRA endothelin receptor type A
EGF epidermal growth factor
EGF-L epidermal growth factor like repeat
EGFR epidermal growth factor receptor
EMT epithelial-to-mesenchymal transition
FAK focal adhesion kinase
FBG fibrinogen like globe
FGFR fibroblast growth factor receptor
FNIII fibronectin type III like repeat
GMEM glial/mesenchymal extracellular matrix protein
HepII Heparin binding domain II
HNF-4α hepatocyte nuclear factor 4α
HSPG heparan sulfate proteoglycan
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LEF/TCF lymphoid enhancer-binding factor, T cell
factor
LPS lipopolysaccharide
MAL myocardin related transcription factor
MAPK mitogen activated protein kinase
MCP1 monocyte chemotactic protein-1
miR micro RNA
MMP matrix metalloprotease
NFκB nuclear factor kappa-light-chain-enhancer
of activated B cells
NK cell natural killer cell
PAMP pathogen associated molecular pattern
PDGFRα/β platelet dervied growth factor receptor-α/-β
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PLC phospholipase C
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Prx-1 peroxiredoxin -1
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TGF transforming growth factor
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TNF tumor necrosis factor
TRAIL tumour necrosis factor related apoptosis
inducing ligand
VEGFA vascular endothelial growth factor
Introduction
Today it is well accepted that the microenvironment plays
an essential role in inflammatory diseases (Schafer and
Werner 2008) and cancer (Marx 2008). In particular in
cancer a normal tissue architecture has a tumor suppressive
function (Bissell and Labarge 2005; Bissell and Radisky
2001). Chronic inflammation can cause cancer and thus,
similar mechanisms involving the role of the microenvi-
ronment might underlie both pathologies. The microenvi-
ronment is composed of a complex extracellular matrix
(ECM) and the embedded cells. The information encoded
by the ECM can be of a mechanical as well as of a signaling
nature. In this review we will summarize current knowledge
about the roles of the ECM molecule tenascin-C during
inflammation and tumorigenesis, its mechanistic basis and
how this knowledge could be used to combat tenascin-C-
associated pathologies such as chronic inflammation and
cancer. Moreover, we will also elaborate on the functions of
tenascin-C as an architectural molecule and highlight evi-
dence for its direct signaling nature.
Structure and expression pattern of tenascin-C
The presence of tenascin-C was discovered more than
20 years ago in gliomas, in muscle tissue and in the nervous
system, hence the different names for this molecule:
myotendinous antigen, glial/mesenchymal extracellular
matrix protein (GMEM), cytotactin, J1 220/200, neuro-
nectin and hexabrachion (reviewed in Chiquet-Ehrismann
and Chiquet 2003; Chiquet-Ehrismann et al. 1994).
Tenascin-C is the founding member of a family of extracel-
lular matrix glycoproteins comprising tenascin-X (termed
tenascin-Yin the chicken), -R and -Win addition to tenascin-
C. Its name, coined by Ruth Chiquet-Ehrismann (Chiquet-
Ehrismann etal. 1986), represents a combination of the Latin
verbs “tenere“ and “nasci“ (to be born, to grow, to develop),
which provided the roots of the English words “tendon“ and
“nascent“, and reflect the location and developmental
expression of the protein observed at that time.
The human tenascin-C gene locus of 97`680 bp (Gherzi
et al. 1995) is located on chromosome 9q33. The tenascin-
C gene was first determined to comprise 28 exons separated
by 27 introns (Gherzi et al. 1995). Subsequently, two
additional exons, AD1 (Sriramarao and Bourdon 1993) and
AD2 (Mighell et al. 1997) were identified, thus resulting in
a total number of 30 exons. The first exon is untranslated
and translation starts in exon 2. The transcript is 8150 bp
long encoding a protein of a maximal putative length of
2385 amino acids (Hancox et al. 2009; Jones et al. 1989;
Pas et al. 2006) (Fig. 1). Tenascin-C exhibits a modular
organization consisting of an N-terminal region containing
a chaperone-like sequence that forms coiled coil structures
and interchain disulfide bonds that are essential for subunit
oligomerization into hexamers. Human tenascin-C com-
prises 14.5 epidermal growth factor (EGF)-like repeats,
30–50 amino acids in length, which contain six cysteine
residues involved in intrachain disulfide bonds. Up to 17
fibronectin type III domains (FNIII) are present that are
about 90 amino acids in length and that are composed of
seven antiparallel β-strands arranged in two sheets. The
number of fibronectin type III domains is generated by
alternative splicing, but the underlying mechanisms are
little understood, although there is evidence that the
proliferative state of a cell (Borsi et al. 1994), extracellular
pH (Borsi et al. 1996), TGFβ1 (Zhao and Young 1995) and
the splicing factor sam68 (Moritz et al. 2008) are involved.
At least nine different FNIII domains are differentially
included or excluded by RNA splicing. This can generate a
considerable diversity in normal tissue such as in the
nervous system (Joester and Faissner 2001), teeth (Sahlberg
et al. 2001), human skin (Latijnhouwers et al. 1996), human
fetal membranes (Bell et al. 1999), avian optic tectum
(Tucker 1998), corneas (Ljubimov et al. 1998), gamma
irradiated tissue (Geffrotin et al. 1998), tissue chronically
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affected by asthma (Matsuda et al. 2005) and, in cancer
tissues (Adams et al. 2002; Carnemolla et al. 1999; Derr et
al. 1997; Dueck et al. 1999; Mighell et al. 1997; Richter et
al. 2009). The different tenascin-C splice forms may cause
distinct but yet unknown cell responses. The C-terminal
fibrinogen globular domain (FBG) resembling the β- and
γ-chains of fibrinogen, 210 amino acids in length, forms
intrachain disulfide bonds (Fig. 1). The tenascin-C protein
displays 23 potential glycosylation sites, two in the
assembly domain, two in the EGF repeats, 18 in the FNIII
repeats and one in the FBG domain. Erickson and cow-
orkers observed that tenascin-C purified from human glioma
cells is indeed glycosylated, probably even to a higher extent
than fibronectin (Taylor et al. 1989). Glycosylation and
alternative splicing affect the molecular weight of the
tenascin-C protein and could explain the wide range between
190 and 330 kDa of the tenascin-C monomer.
Tenascin-C has a tightly regulated pattern of expression
which has been reviewed in detail elsewhere (Tucker and
Chiquet-Ehrismann 2009). In addition to the high levels
expressed in the tumor stroma, it is significantly up-regulated
in response to tissue injury (Orend and Chiquet-Ehrismann
2006). Tenascin-C expression can be induced by various
pro- and anti-inflammatory cytokines (see below) and by
growth factors that are mostly secreted by stromal cells. In
addition, hypoxia, reactive oxygen species, and mechanical
stress, which are also present in inflamed and tumor tissue,
induce tenascin-C expression. In contrast, glucocorticoids
(Cella et al. 2000) and GATA-6 (Ghatnekar and Trojanowska
2008) suppress tenascin-C expression. Signaling causing
activation of transcription factors such as TCF/LEF, NfkB,
c-Jun, Ets, SP1, and Prx-1 is involved in tenascin-C gene
transcription(OrendandChiquet-Ehrismann2006). Recently,
Notch1 and Notch2 signaling (Sivasankaran et al. 2009)a n d
HNF-4α (Ishikawa et al. 2008) were also described to
induce tenascin-C transcription in gliomas and mammary
epithelial NMuNG cells, respectively. In addition, a combi-
nation of signals induced by ectopic expression of c-myc and
VEGFA in the mammary epithelium also induced tenascin-C
(Calvo et al. 2008). Tenascin-C RNA levels can also be
downregulated by miR-335, and low expression levels of
miR-335 (allowing high tenascin-C expression) appear to be
causally linked to lung metastasis in breast cancer (Tavazoie
et al. 2008). Tenascin-C is cleaved by matrix metallopro-
teases and serine proteases, thus potentially releasing cryptic
sites that may create adhesive sites for cell adhesion
receptors (Table 1). Indeed, MMP2 cleavage of tenascin-C
generated a cryptic adhesive site within the FNIII A2 domain
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Fig. 1 Tenascin-C structure and binding partners a The exon/intron
structure of the human tenascin-C gene on chromosome 9q33 and the
organization into the different protein domains is depicted schemat-
ically. Information on the exon/intron organization is based on Hancox
et al. (2009) and analysis of sequence entries in the EMBL sequence
data bank. Organization of tenascin-C into an assembly domain,
EGF-L, constant (grey) and alternatively spliced in FNIII repeats
(black) and the C-terminal FBG. Tenascin-C-interacting molecules
are shown at the bottom of the figure. CALEB, chicken acidic
leucine-rich EGF like domain containing brain protein; EGFR,
epidermal growth factor receptor; NaN, sodium channel subunit
β2; RPTPβ, receptor protein tyrosine phosphatase β/ζ (Orend and
Chiquet-Ehrismann, 2006). b The appearance of purified tenascin-C
protein as a hexamer upon electron microscopy. Taken from (Orend
and Chiquet-Ehrismann, 2006). c Tenascin-C present in matrix tubes
of paraffin preserved human colorectal carcinoma tissue is visualized
by immunohistochemistry
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YTITIRG sequence that is homologous to a similar sequence
in the FBG domain, bound to the heparan sulfated side
chains of syndecan-4 and thus caused clustering and
activation of β1 integrins and cell spreading (Saito et al.
2007). Cleavage of tenascin-C by MMP2 also caused
removal of the alternativley spliced in FNIII repeats A3/A4
and B-D (Siri et al. 1995). In vitro cleavage of tenascin-C by
Table 1 Tenascin-C, binding partners and cell responses
TN-C domains Ligand Effect Reference
TN-EGF-repeats Counteradhesive for fibroblasts, neurons, glial cells Spring et al. 1989; Prieto et al. 1992
Neuronal outgrowth, neurite repulsion Fischer et al. 1997; Gotz et al. 1997





EGFR EGFR phosphorylation Swindle et al. 2001
PLCγ activation; fibroblast migration Iyers et al. 2007
TNfnIII1-3 Cerebellar neuron attachment Gotz et al. 1997
Suppression of milk protein synthesis in mammary
epithelium, tissue involution
Jones et al. 1995
TNfnIII1-5 Fibronectin T lymphocyte inhibition of β1 integrin adhesion Hauzenberger et al. 1999
TNfnIII2-6 Integrins Cell attachment Prieto et al. 1992
TNfnIII3 αvβ3, α2β1 EC elongation Sriramarao and Bourdon 1993
αvβ3, αvβ6 Glioma spreading Prieto et al. 1993
αvβ3, α9β1, αvβ6 Colon carcinoma spreading Yokosaki et al. 1996
αvβ1 Neuron attachment, inhibition of growth Probstmeier and Pesheva 1999
α8β1 Smooth muscle cell, astrocyte adhesion Schnapp et al. 1995
α8β1 K562 cell adhesion Denda et al. 1998
TNfnIII3-5 Perlecan CHO cells, incorporation of TNC into fibronectin-rich
matrix
Chung and Erickson 1997
TNfnIII3,5,6 αvβ1 Glioma process extension Giese et al. 1996; Phillips et al. 1998
TNfnIIIA-D Attachment of uterine epithelia, reduced adhesion and
implantation
Julian et al. 1994
Matsuda et al. 1999
Annexin II Corneal epithelia proliferation, migration, wound healing.
Endothelia, loss of focal adhesions, increase in
mitogenesis and migration
Chung and Erickson 1994; 1996
TNfnIIIA1A2 Fibronectin Inhibition of lymphocyte activation Puente Navazo et al. 2001; Parekh
et al., 2005 CD3 Inhibition of tumor infiltrating lymphocytes, inhibition of
proliferation, blocking secretion of cytokines
TNfnIIIA2 HS, Syndecan-4 Cell spreading Saito et al. 2007
Binding of YTITIRG to the HS side chain activates
syndecan-4 and clustering with β1 integrins
TNfnIIIA3 MMP-2, MMP-3 Fetal membranes, tissue remodeling Bell et al. 1999
TNfnIIID α7β1 Neurite outgrowth Mercado et al. 2004
contactin Activation of PKC and calmodulin kinase Michele and Faissner 2009
TNfnIII6-8 Fibronectin Incorporation of TNC into matrix Chiquet-Ehrismann et al. 1991;
Chung et al. 1995
TNfnIII7-8 Modulation of FN-dependent induction of c-fos,
collagenase, stromelysin and gelatinase expression in
synovial fibroblasts
Tremble et al. 1994
TN-FBG Integrin αvβ3 Attachment of integrin transfected CHO cells Yokoyama et al. 2000
bFGF-induced sprouting, elongation of aortic ECs Schenk et al. 1999
HSPG-dependent induction of bone marrow mononuclear
cell, supports growth in integrin independent manner
Seiffert et al. 1998
Phosphacan/RPTPζ/β 12nM kd binding, inhibits neuronal adhesion Aukhil et al. 1993
TLR4 Activation of TLR4 and induction of inflammatory cytokines Midwood et al. 2009
Summary of mapped interaction sites within tenascin-C and transmembrane receptors, MMPs and ECM molecules. The described cellular
responses and corresponding signaling pathways are listed. Full references are found at the end of the article. bFGF, basic fibroblast growth factor,
FN, fibronectin, HS, heparan sulfate, HSPG, heparan sulfated proteoglycan, PKC, protein kinase C, MMP, metalloprotease
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human melanoma cells (Imai et al. 1994). Cell contact with
tenascin-C also induced expression of matrix metallopro-
teases (Tremble et al. 1994), thus presenting a positive
feedback loop between induction of metalloproteases by
tenascin-C and cleavage of tenascin-C by these enzymes. It
is most likely that hexameric, monomeric and protease-
cleaved tenascin-C exhibit distinct functions, although the
full extent of these functions is not currently clear.
Tenascin-C binds to ECM molecules such as fibronectin,
perlecan, aggrecan, versican, brevican (Fig. 1) and presum-
ably many more ECM molecules that remain to be identified.
ItspromiscuousbindingtoavarietyofECMmoleculesandits
hexameric organization may provide tenascin-C with cross-
linking functions, thus potentially modulating the architecture
andresilienceoftissues.Cellscaninteractwithtenascin-Cvia
cell-surface receptors including integrins α2β1,α7β1, α9β1
and αvβ3, syndecans 1 and 4, annexin II, and epidermal
growth factor receptor (EGFR) amongst others (Fig. 1,
Table 1). These data are extensively reviewed elsewhere
(Orend and Chiquet-Ehrismann 2006). Thus tenascin-C is
equipped not only to modulate the cellular environment, but
also to influence the behaviour of cells. However, the
resulting cell responses and their potential in vivo relevance
are still poorly understood at a mechanistic level.
Overview of the response to tissue injury
The response to tissue injury is a highly orchestrated process.
It proceeds through three distinct but overlapping phases;
inflammation, tissue rebuilding and tissue remodelling (for
more detailed reviews see (Clark 1993; Midwood et al.
2004b)). Inflammation is a critical and immediate response
to tissue injury and infection. Pattern recognition receptors
(PRRs) recognize both pathogen- and damage-associated
molecular patterns (PAMPs and DAMPs) and in response
stimulate the expression of pro-inflammatory genes (Gordon
2002). These include cytokines and chemokines, which
attract immune cells including neutrophils, myeloid cells and
lymphocytes to the site of injury or infection. These cells
mediate removal of the injurious stimuli and dead or
damaged tissue. They also initiate the healing process by
inducing the proliferation of other cell types, including
fibroblasts and endothelial cells (EC), and stimulate their
migration to the site of injury (Clark 1993;M i d w o o de t
al. 2004b).
Immediately upon injury, a provisional ECM consisting
predominantly of fibrin and plasma fibronectin is synthe-
sized. Deposition of this matrix temporarily fills the wound
bed and prevents excessive blood loss. Assembly of new
ECM upon this scaffold is vital in order to replace lost
and damaged tissue and restore the architecture of tissue.
Upon activation, cells such as fibroblasts migrate into the
provisional matrix where they assemble fibronectin-rich
granulation tissue. This in turn forms a scaffold for the
subsequent deposition of collagen types I and III and other
ECM molecules. EC re-vascularize the new tissue and
fibroblasts differentiate into myofibroblasts, which contract
the ECM to bring the margins of the wound together. The
resultant scar tissue is then remodeled and collagen cross-
linked over the following years, although it fails to exactly
recapitulate the cellularity, vascularity, and tensile strength
of the original tissue (Clark 1993; Midwood et al. 2004b).
Regulation of each of these phases is vital: over-
enthusiastic inflammation can lead to damage of healthy
tissues, too little matrix deposition results in chronic non-
healing wounds, whereas too much is the hallmark of
fibrotic disease, including pulmonary fibrosis and liver
cirrhosis; excessive myofibroblast contraction mediates
hypertrophic scarring commonly associated with burns
(Clark 1993; Midwood et al. 2004b).
The role of tenascin-C in tissue injury
A. Inflammation
Tenascin-C expression is induced at sites of inflammation,
apparently regardless of the location or type of causative
insult. Expression is observed upon both tissue injury, for
example during incisional wounding or photo-damage to
the skin (Betz et al. 1993; Filsell et al. 1999), tendon rupture
(Riley et al. 1996) and asbestos-induced lung damage
(Kaarteenaho-Wiik et al. 2000). Tenascin-C is also induced
by infections, for example in the lungs of tuberculosis
patients (Kaarteenaho-Wiik et al. 2000), upon infection with
staphylococcus aureus (Paallysaho et al. 1993) and in the
cervical epithelium of patients with human papilloma virus
(Tiitta et al. 1992). This pattern of expression suggests that
tenascin-C comprises part of a common, global inflammatory
response.
Tenascin-C expression is induced rapidly upon tissue
injury. In normal human skin, low levels of tenascin-C
expression are restricted to the dermal-epidermal junction,
eccrine glands and to large blood vessels (Lightner et al.
1989; Schalkwijk et al. 1991b). The appearance of tenascin-
C mRNA and protein often precedes obvious signs of tissue
damage or inflammation induced in human skin by UVB
(Seite et al. 2000), gamma irradiation (Geffrotin et al. 1998;
van der Vleuten et al. 1996), excisional wounds and punch
biopsies (Betz et al. 1993; Latijnhouwers et al. 1996). Early
induction of tenascin-C expression is also observed during
hapten-induced allergic reaction in mice (Kusubata et al.
1999) and in incisional wounds in rats (Mackie et al. 1988)
and mice (Fassler et al. 1996). During the acute inflamma-
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of increased immune cell infiltration. It co-localizes with
polymorphonuclear lymphocyte cell infiltration in the
inflamed human dermis upon application of leukotriene-
B4 (Seyger et al. 1997), in areas of mononuclear cell
infiltrates, in degenerate tendons resulting from rotator cuff
rupture (Riley et al. 1996), at sites of leukocyte accumu-
lation in patients with myocarditis (Tsukada et al. 2009) and
during experimental liver inflammation in mice (El-Karef
et al. 2007).
Tenascin-C expression is particularly well documented
in lung inflammation. It associates with inflammatory foci
in inflamed bronchi of smokers (Amin et al. 2003) and in
patients with interstitial lung diseases such as interstitial
pneumonia and sarcoidosis (Kaarteenaho-Wiik et al. 1998;
Kuhn and Mason 1995). Expression is also increased in the
subepithelial ECM of patients with bronchial asthma, a
disease characterized by chronic airway inflammation,
where it correlates with the grade of bronchial infiltration
of mast cells and eosinophils (Amin et al. 2000; Karjalainen
et al. 2000). Matsuda et al. (2005) demonstrated that a
single nucleotide polymorphism in the alternatively spliced
FNIII-D domain of tenascin-C is associated with a high
risk of developing asthma. Molecular modeling of the
resultant amino acid substitution (Leu1677Ile) demon-
strated that steric hindrance by a isoleucine side chain
may hinder hydrophobic interactions at the outer edge of
the beta sheet, causing domain instability. The authors
propose that this change may alter FNIII-D domain
elasticity and result in changes in the integrity or stiffness
of the asthmatic airway (Matsuda et al. 2005). Tenascin-C-
induced PDGFRβ signaling that causes smooth muscle cell
expansion contributes to airway obstructions in the lung.
This mechanism might also be relevant in Aspergillus
fumigatus-induced asthma in the mouse and in pulmonary
hypertension in humans since a high tenascin-C expression
correlated with high expression of PDGFRβ and SMC
proliferation in the diseased lung (Cohen et al. 2009).
Nakahara et al. (2006) subsequently demonstrated that
tenascin-C-null mice are protected from experimentally
induced asthma due to a dampened Th2 cell response
(Nakahara et al. 2006). Th2 lymphocyte activation plays a
fundamental role in the pathogenesis of asthma (Busse and
Lemanske 2001). Lower levels of cytokines secreted by
Th2 CD4+ T lymphocytes including IL-5, IL-4, IL-13,
were detected in the bronchiolar lavage fluid of tenascin-C-
null mice. Subsequent stimulation of IgE synthesis by B
lymphocytes, recruitment and prolonged survival of eosi-
nophils and airway activation were also attenuated in null
mice. In addition, lower levels of MCP-1 and MMP-9
induction were observed in tenascin-C-null mice (Nakahara
et al. 2006). Together these data indicate that the role of
tenascin-C in the pathogenesis of bronchial asthma may lie
in mediating lymphocyte trafficking to the inflamed
bronchial mucosa and/or activation of T cells.
A role for tenascin-C in stimulating lymphocyte migra-
tion is suggested by data that demonstrate that tenascin-C
supports primary human peripheral blood and tonsillar
lymphocyte adhesion and rolling (Clark et al. 1997). In
addition, tenascin-C-null mice exhibit reduced lymphocyte
infiltration and lower levels of IFN, TNF and IL-4 mRNA
upon concanavalin A-induced liver injury in mice (El-Karef
et al. 2007). However, tenascin-C appears to exhibit a cell-
type specific effect on migration; it inhibits monocyte
chemotaxis in vitro (Loike et al. 2001) and tenascin-C-null
mice exhibit increased migration of monocytes and macro-
phages in mammary tumor stroma (Talts et al. 1999).
There is also evidence that tenascin-C can directly
regulate the activation of lymphocytes. Addition of exog-
enous tenascin-C to mouse spleen lymphocytes cultured on
fibronectin substrates, stimulates secretion of IL5, IL13,
IFN and IgE (Nakahara et al. 2006) and tenascin-C also
induces calcium mobilization in Jurkat T lymphocytes
(Kuhn and Mason 1995). Whilst these data suggest a
role for tenascin-C in promoting T cell responses there is
also evidence that it limits their inflammatory function
(Kuznetsova and Roberts 2004). Tenascin-C inhibits the
activation of human peripheral blood T cells induced by
natural antigens (Ruegg et al. 1989), by immobilization on
CD3 and fibronectin (Hemesath et al. 1994) and by anti-
CD28, ICAM-1, or laminin (Hibino et al. 1998). It also
significantly inhibits anti-CD3 and mitogen-induced prolif-
eration and IFNγ production in human peripheral blood
lymphocytes and lymphocytes isolated from lung tumors
(Parekh et al. 2005). The alternatively spliced domains
FNIII-A1-3 mediate the suppression of anti CD3/fibronectin-
induced proliferation, and TNF and IFNγ secretion (Puente
Navazo et al. 2001), although the molecular mechanism
remains unclear. It is unlikely that tenascin-C affects protein
kinase C signaling pathways required for Tcell activation, as
it does not prevent T cell activation induced by the protein
kinase C agonist PMA (Parekh et al. 2005). It may therefore
interfere with other pathways, for example, the activation
of Rho-induced proliferation (Woodside et al. 1998),
given the ability of tenascin-C to suppress Rho activation
in fibroblasts (Wenk et al. 2000). Consistent with a role in
suppressing the immune response, tenascin-C-deficient
mice develop progressive inflammation and glomerular
damage in experimental venom-induced glomerulonephri-
tis (Nakao et al. 1998). These mice also develop severe
dermatitis in response to 2,4-dinitrofluorobenzene and
exhibit prolonged infiltration of polymorphonuclear cells
(Koyama et al. 1998).
In addition to a role for tenascin-C in modulating T cell
behavior to influence the adaptive immune response, we
have demonstrated that tenascin-C contributes to driving
292 K.S. Midwood, G. Orendinnate immunity. Tenascin-C stimulates the production of
pro-inflammatory cytokines TNFα, IL-6 and IL-8 in primary
human macrophages and synovial fibroblasts, via activation
of Toll-like receptor 4 (TLR4) mediated signaling pathways
(Midwood et al. 2009). It can also stimulate cytokine and
MMP synthesis in murine synovial fibroblasts via activation
of α9 integrins (Kanayama et al. 2009). Tenascin-C induces
inflammation in vivo when injected into the joints of mice,
and tenascin-C-null mice exhibit accelerated resolution of
joint inflammation and are protected from persistent inflam-
mation and erosive joint disease (Midwood et al. 2009).
Together these data demonstrate that tenascin-C can influ-
ence many aspects of immunity and that its precise role at
sites of inflammation is defined by context: for example the
site and mode of tissue injury, or the participating cell types
(Table 2).
Table 2 Potential roles of tenascin-C during tissue repair and tumorigenesis
Stage Function Key References
Inflammation Adaptive immunity Promotes lymphocyte migration Clark et al. 1997
Stimulates Th2 cell activation Nakahara et al. 2006
Inhibits T cell activation Kuznetsova and Roberts 2004
Innate immunity Inhibits myeloid cell migration Loike et al. 2001; Talts et al. 1999;
Midwood et al. 2009 Stimulates TLR4 mediated cytokine production
Re-epithelialization Keratinocyte adhesion and migration Matsuda et al. 1999; Katz et al. 2006;
Ishii et al. 2008 Epithelial cytodifferentiation
Tissue rebuilding Cell migration ECM-cell interactions Chiquet-Ehrismann and Chiquet 2003;
Tran 2005 GFR activation
Cell proliferation GRF activation Swindle et al. 2001
ECM synthesis Cell response to growth factors El-Karef et al. 2007
Synthesis of GF Nakao et al. 1998
ECM assembly Cross linking of ECM Lundell et al. 2004
Angiogenesis EC adhesion and migration Chung et al. 1996
Cell response to growth factors Murphy-Ullrich et al. 1991
Release of EPCs from bone marrow Ballard et al. 2006
Serum levels of VEGFA in tumor mice Tanaka et al. 2004
Tissue remodelling Wound contraction Myofibroblast differentiation, migration,
contraction
Tamaoki et al. 2005
Cell clearance Stimulates apoptosis Nakao et al. 1998; Wallner et al. 2004
Metastasis Cancer cells: reduced adhesion,
enhanced proliferation
Inhibition of syndecan-4 Huang et al. 2001;
Activation of Wnt signaling Ruiz et al. 2004
Induction of EDNRA Lange et al. 2007
Cancer cells: enhanced
migration and invasion
Enhanced migration in response to
promigratory factors
Lange et al. 2008
Induction of MMPs Tremble et al. 1994; Kalembeyi et al.
2003; Imai et al. 1994; Siri et al.




Downregulated expression blocks lung
metastasis
Tavazoie et al. 2008; Calvo et al. 2008
Present in matrix channels of metastatic
melanomas
Kaariainen et al. 2006
Present in matrix conduits of the thymus Drumea-Mirancea et al. 2006
Carcinoma associated
fibroblasts
Secrete tenascin-C and HGF; necessary for
invasion of colorectal carcinomas
De Wever et al. 2004
Lumen formation and secretion of
tenascin-C into tubes
Gaggioli et al. 2007
Tenascin-C can influence a wide variety of physiological processes during tissue repair and cancer. Tenascin-C exhibits context-specific regulation
of innate and adaptive immune cell function during the early inflammatory phase, and stimulates the subsequent re-epithelialization, tissue
rebuilding, and tissue remodeling by promoting cell migration and proliferation, ECM synthesis and assembly, angiogenesis, wound contraction
and cell death during tissue repair. During tumor angiogenesis, invasion and metastasis tenascin-C induces pro-migratory and pro-proliferative
signaling, activates MMPs and is expressed in matrix channels that are associated with metastastic cancer. ECM, extracellular matrix, EDNRA,
endothelin receptor type A, EPC, endothelial progenitor, GFR, growth factor receptor, Th2, T helper cells, TLR, toll like receptor
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In the first 24 h following dermal wounding, keratinocytes
proliferate and migrate through the fibrin clot. This
mediates early wound closure that is key to preventing
further microbial invasion (Clark 1993; Midwood et al.
2004b). In addition to the expression of tenascin-C in areas
of immune cell infiltration during inflammation, it is also
observed within 24 h at the dermal/epidermal junction
underneath migrating and proliferating keratinocytes
(Betz et al. 1993; Mackie et al. 1988). In situ hybridization
demonstrates that keratinocytes are the major source of this
tenascin-C (Latijnhouwers et al. 1997). Strong expression
of tenascin-C is also observed underneath the hyper-
proliferative epidermis in patients with acne (Knaggs et al.
1994), psoriasis(Gerritsenetal.1997) and blistering diseases
(Schenk et al. 1995). However it is absent from keratinocyte
pathologies that do not proceed via hyperproliferative path-
ways, including X-linked recessive ichthyosis, autosomal
dominant ichthyosis vulgaris and non-erythrodermic lamellar
ichthyosis (Schalkwijk et al. 1991a). During development of
the chick cornea, keratinocytes emigrate from tenascin-C
rich areas during embryonic stage 27 (Kaplony et al. 1991).
Furthermore, corneal suture wounds in tenascin-C-null mice
are devoid of migrating keratinocytes (Matsuda et al. 1999).
These data suggest that tenascin-C may play a role in
regulating epithelial cell functions, such as promoting their
proliferation and migration.
Immortalized human epithelial corneal cells secrete a
tenascin-C- and laminin-rich plaque that is essential for
early adhesion events (Katz et al. 2006), and isolated
primary human epidermal keratinocytes maintain a rounded
morphology on tenascin-C substrates (Latijnhouwers et al.
1997), suggesting that tenascin-C may promote adhesion
and migration during re-epitheliazation. Moreover, in
studying the development of the prostate, (Ishii et al.
2008) identified tenascin-C as a morphogenic signal that
drives epithelial differentiation and function by up-regulating
androgen receptor expression (Ishii et al. 2008). Thus
tenascin-C may also promote epithelial cytodifferentiation
during wound repair.
B. Tissue rebuilding
Towards the end of the inflammatory phase of tissue repair,
tissue rebuilding begins. In incisional or abrasion wounds
to the dermis, tenascin-C expression peaks at this point. It
increases at wound edges of the dermis associated with
activated fibroblasts, and then extends into connective
tissue and is observed throughout the dermis. High levels
are also found in the new granulation tissue (Betz et al.
1993; Fassler et al. 1996; Latijnhouwers et al. 1996;
Mackie et al. 1988). Persistent tenascin-C expression
correlates with excessive matrix deposition in patients with
fibrotic diseases including chronic liver disease (Van Eyken
et al. 1990; Yamada et al. 1992) and several fibrotic lung
disorders such as pulmonary fibrosis (Kaarteenaho-Wiik
et al. 1998). Tissue tenascin-C levels are increasingly used
as a predictive marker for fibrosis (Lieber et al. 2008;
Paivaniemi et al. 2008). Tenascin-C-null mice exhibit thinner
stromata during corneal suture wounds with reduced
fibronectin deposition (Matsuda et al. 1999). Similarly,
lower levels of fibronectin were detected in the granulation
tissue during healing of dermal excisional wounds in
tenascin-C-null mice (Forsberg et al. 1996), and only small
and immature granulation tissue was observed during
experimental kidney injury (Nakao et al. 1998). Together
these data suggest a role for tenascin-C in promoting tissue
rebuilding during wound healing (Fig. 2).
Cell proliferation and migration
The proliferation of cells in healthy tissue adjacent to the
wound and their migration into the wound site is essential
for tissue rebuilding. Upon dermal injury, fibroblast infiltra-
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Fig. 2 Tenascin-C in tissue
repair The interaction of
tenascin-C with distinct cell
types throughout tissue repair
and the respective cell responses
are shown during the different
phases of the response to tissue
damage
294 K.S. Midwood, G. Orendaround 4 days after injury and is the key rate-limiting step of
tissue rebuilding (McClain et al. 1996).
Tenascin-C has diverse effects on cell migration in vitro
that reflect differences in cell type, species, and the assay
used in each study (Trebaul et al. 2007). For example,
human corneal fibroblasts migrate on tenascin-C substrates
but soluble tenascin-C added to these cells on collagen
substrates inhibits migration (Schmidinger et al. 2003).
Tenascin-C induces a migratory phenotype in mouse
NIH3T3 fibroblasts cultured on a fibrin-fibronectin matrix;
cells remain rounded and do not form actin stress fibers or
focal adhesions but instead form extended actin-rich
filopodia. These changes in morphology are mediated by
inhibition of FAK and RhoA activity (Midwood and
Schwarzbauer 2002; Wenk et al. 2000). Tenascin-C also
induces a migratory phenotype in human, rat, and mouse
fibroblasts,and ingliomacells platedonfibronectinsubstrata.
Again, FAK activation was inhibited by tenascin-C, but here
down-regulation of tropomyosin-1 and RhoA, rather than
inhibition of RhoA was proposed to decrease actin stabiliza-
tion (Lange et al. 2007;R u i ze ta l .2004). In both cases,
tenascin-C acts by blocking the interaction of fibronectin
with cell-surface syndecan-4 (Huang et al. 2001;M i d w o o d
et al. 2004a) by binding directly to FNIII13 in the HepII
domain of fibronectin (Huang et al. 2001). Tenascin-C also
possesses heparin-binding activity (Marton et al. 1989)
raising the possibility that it may additionally compete for
binding to syndecan HSPG side chains. Indeed, one of the
heparin-binding sites has been mapped to the FBG domain
of tenascin-C (Aukhil et al. 1993; Fischer et al. 1995). The
FBG posseses no fibronectin binding activity (Chung et
al. 1995), but it can promote migration of human fibro-
blasts within 3D fibrin-fibronectin gels (Trebaul et al.
2007). These data suggest that heparin binding may also
be sufficient to mediate changes in cell morphology
required for migration.
The epidermal growth factor-like (EGF-L) domain of
tenascin-C also plays a role in regulating fibroblast prolifer-
ation and migration. The EGF-L repeats, Ten1-2, Ten11-13
and Ten14 induce EGF receptor (EGFR) phosphorylation and
stimulate MAP kinase activation and mitogenesis in the NR6
fibroblast cell line (Swindle et al. 2001). Ten14 was also
shown to bind to EGFR with low affinity and to induce
migration through activation of PLCγ and m-calpain (Iyer et
al. 2008). Tenascin-C activation of EGFR also stimulates
Rac activity in myofibroblasts which, via inhibition of Rho
activation, promotes their invasion in collagen gels (De
Wever et al. 2004). In direct contrast to other EGFR ligands,
which induce migration and proliferation at similar con-
centrations, tenascin-C EGF-L repeats induce mitogenesis at
high micromolar levels and migration at lower levels
(Swindle et al. 2001). The Kd of Ten14 for EGFR is
74 μM, 3 orders of magnitude weaker than EGF. This is due
to lack of a C terminal loop in Ten14 that mediates high-
affinity interactions of EGF. The resultant rapid off rate is
proposed to be preferential for cell motility at low concen-
trations (Tran et al. 2004;T r a ne ta l .2005). Thus, different
domains of tenascin-C can affect cell migration or prolifer-
ation by different mechanisms, including modulation of cell
adhesion to the ECM or via direct interactions with cell-
surface growth factor receptors.
ECM synthesis
Deposition of new ECM is key to restoring tissue
architecture and functionality (Clark 1993). Tenascin-C
may promote matrix deposition or fibrosis by increasing
pro-collagen synthesis. In a model of immune-mediated
hepatitis, collagen deposition was reduced in tenascin-C-
null mice. This occurred at the level of gene transcription
with a 50% reduction in collagen I mRNA induction and
failure to induce any collagen type III transcripts (El-Karef
et al. 2007). These studies do not rule out a role for
tenascin-C in direct transcriptional control of collagen
genes, but they do offer several other potential mechanisms
of action. In this model, weekly injections of concanavalin
A induce local inflammation, which causes continuous
cellular injury leading to increased collagen deposition and
eventual fibrosis. Tenascin-C-null mice exhibit attenuated
liver inflammation with reduced numbers of infiltrating
lymphocytes concomitant with lower levels of cytokines
such as IFNγ, TNF and IL-4 mRNA. These mice also
demonstrate low numbers of activated hepatic stellate cells
and myofibroblasts, the cellular source of procollagens, as
well as reduced induction of transforming growth factor
(TGF)-β1 mRNA, a growth factor that stimulates collagen
transcription (El-Karef et al. 2007). Thus the failure of mice
to induce collagen transcription in the absence of tenascin-
C could simply result as a consequence of an attenuated
inflammatory response that fails to stimulate subsequent
recruitment of collagen-synthesizing cells and TGFβ1
expression. Conversely tenascin-C could have direct effects
on each stage of the progression of hepatitis to fibrosis
(Table 2, Fig. 2).
Indeed, tenascin-C can affect stromal cell activity and
growth factor synthesis independently of its effects on
inflammation. Tenascin-C-null mice are unable to resolve
renal inflammation in response to snake venom-induced
glomerulonephritis (Nakao et al. 1998). In wild-type mice
destruction of the kidney mesangial structure caused by
inflammation is reversible and heals spontaneously. How-
ever, renal damage induced in tenascin-C-null mice persists
and can be fatal. In this model, renal fibrosis is not likely to
be attributable to reduced inflammation in the absence of
tenascin-C, as equal numbers of infiltrating immune cells
were observed in wild-type and null mice. Instead, lower
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regeneration of tissue were observed. Furthermore, induc-
tion of PDGF was reduced and induction of TGFβ1,
collagen type VI and fibronectin delayed (Nakao et al.
1998). The proliferation of mesangial cells isolated from
wild-type mice in response to PDGF and TGFβ1 can be
blocked by an antibody to the EGF-L repeats of tenascin-C.
Conversely, cells isolated from tenascin-C-null mice do not
proliferate inresponsetoPDGForTGFβ (Nakaoetal. 1998),
suggesting that tenascin-C modulates cellular response to
growth factors. These findings are consistent with data
showing that proliferation of mouse 3T3 fibroblasts induced
by EGF was enhanced when tenascin-C was added to the
culture medium. This effect was mediated by the constitu-
tively expressed FNIII domains, but not by the alternatively
spliced domains (End et al. 1992). The precise details of the
molecular mechanism(s) by which tenascin-C regulates the
cellular response to growth factors are not known. Tenascin-
C may bind directly to growth factors in order to increase
local concentrations at the cell-surface, in a manner similar
to heparin (Goodger et al. 2008). It may increase growth
factor receptor availability at the cell-surface, either by
directly affecting receptor expression, as it appears to do for
androgen receptors (Ishii et al. 2008) and endothelin receptor
type A (EDNRA) (Lange et al. 2007), or by stabilizing
receptor clustering upon ligation, potentially via modulation
of syndecan-4/FGF/FGFR complex formation (Alexopoulou
et al. 2007). Since tenascin-C competed with syndecan-4
binding to fibronectin, it is possible that syndecan-4 is
exclusively available as a coreceptor for growth factor
receptors in the presence of tenascin-C. In summary, in
addition to its role in regulating the inflammatory response,
there is strong evidence that tenascin-C may also play a
direct role in the control of growth factor signaling that
promotes ECM synthesis.
ECM assembly
Tenascin-C interacts directly with many ECM molecules
including fibronectin (Orend and Chiquet-Ehrismann 2006)
(Fig. 1). It can bind to soluble plasma fibronectin in vitro
(Chiquet-Ehrismann et al. 1991; Chung et al. 1995; Ingham
et al. 2004) as well to the fibronectin fibrils of cultured cells
(Chiquet and Fambrough 1984; Chung et al. 1995; Ramos
et al. 1998). Tenascin-C co-localizes to fibronectin fibrils
and to regions of fibronectin deposition and assembly in
vivo (Chiquet and Fambrough 1984; Kusubata et al. 1999;
Riou et al. 1990; Whitby et al. 1991). Fibronectin and
tenascin-C matrix assembly appear to be interdependent
(Ramos et al. 1998) and the recombinant tenascin-C protein
70Ten, which contains the FNIII like repeats and the FBG
domain of tenascin-C inhibits fibronectin matrix assembly
(Midwood and Schwarzbauer 2002). It was demonstrated,
using in vitro solid phase binding assays, that tenascin-C
can bind to fibrillar collagen types I — VI and IX, but not
denatured collagen (Faissner et al. 1990). However, despite
colocalization of tenascin-C and collagen in several tissues,
little evidence exists to show any functional relevance of
this interaction. This is in contrast to tenascin-X a family
member whose deficiency results in Ehlers Danlos syndrome
due to an inability to properly regulate dermal collagen fiber
maturation (Chiquet-Ehrismann 2004).
Tenascin-C also interacts with ECM-resident proteogly-
cans, including members of the lectican family; versican,
neurocan, aggrecan and brevican (Day et al. 2004). The
FNIII3-5 domain binds with high affinity to the highly
conserved G3 domain in aggrecan, versican and neurocan
but exhibits weaker binding to brevican (Day et al. 2004).
Electron microscopy shows that purified hexameric tenascin-
C crosslinks aggrecan-hyaluronan complexes, suggesting a
role in mediating the structural organization of the ECM
(Lundell et al. 2004). This interaction also occurs with
FNIII3-5 of tenascin-R and crystalization of these domains
in complex with the aggrecan C-type lectin domain revealed
a direct protein-protein interaction between the lectin domain
and FNIII4 (Lundell et al. 2004). A role for tenascin-C in
promoting proteoglycan assembly is supported by the fact
that neointima formation during the intimal hyperplasia that
follows longitudinal aortotomy in rats is reduced in tenascin-
C-null mice, with significantly lower levels of alcian blue-
positive proteoglycan deposition (Yamamoto et al. 2005).
Together these data suggest a role for tenascin-C in
promoting ECM synthesis during tissue repair by regulating
cell migration and proliferation, tissue levels of pro-fibrotic
growth factors and cell response to these factors, but they
also indicate a potential role as a structural template that
mediates assembly of ECM components.
Vascular remodeling
New tissue deposited during repair is called granulation
tissue because the formation of new blood vessels gives it a
granular appearance. Revascularization is vital to maintain
the viability of any new tissue. Tenascin-C expression is
highly associated with sites of vascular remodeling during
dermal tissue repair (Betz et al. 1993; Fassler et al. 1996;
Latijnhouwers et al. 1996; Mackie et al. 1988). In the
central nervous system, tenascin-C is expressed by migrat-
ing EC and the kinetics of its expression are linked with
maximal angiogenic activity during infectious, ischemic, and
traumatic processes (Zagzag and Capo 2002). Tenascin-C
expression is also highly associated with angiogenesis in a
wide range of disease states, including cancer, diabetes,
aortic aneurysm (Castellon et al. 2002; Jallo et al. 1997;
Paik et al. 2004), artheriosclerosis (Fischer 2007), ulcerative
colitis (Dueck et al. 1999), inflammatory bowel disease
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vasculitis (Gindre et al. 1995).
During tissue neovascularization, EC undergo pro-
angiogenic activation, disrupting their ECM interactions
and assuming a migratory morphology (Carmeliet 2000;
Ingber 2002). In vitro, tenascin-C is specifically expressed
by sprouting and cord forming bovine aortic EC but not by
non-sprouting, i.e. resting cells (Canfield and Schor 1995;
Schenketal.1999). This angiogenic phenotype was inhibited
when cells were grown in the presence of anti—tenascin-C
antibodies, suggesting that the transition from a resting to
a sprouting phenotype may be promoted by tenascin-C
(Canfield and Schor 1995). And in fact, soluble tenascin-
C reduces focal adhesions in EC (Chung et al. 1996;
Murphy-Ullrich et al. 1991) and enhances EC migration
(Chung et al. 1996).
Studies using a cardiac allograft model demonstrate that
tenascin-C is required for vascularization in mice in vivo.
Upon subdermal transplantation of wild-type cardiac tissue
into a syngenic host, a fibrin clot forms around the allograft
and both the clot and cardiac tissue become vascularized,
resulting in engraftment of viable cardiac tissue. Clot
formation is unaffected in tenascin-C-null mice; however,
these mice fail to form any vascular channels and no
engraftment of cardiac tissue is observed. In wild-type mice
the donor EC were observed to engraft at sites of tenascin-
C expression suggesting that tenascin-C acts to promote EC
homing and incorporation. Indeed, in vitro, rat cardiac
microvascular EC adhered to tenascin-C substrata, but
spreading and monolayer formation were delayed com-
pared to that in cells adherent to fibronectin or collagen.
Futhermore, migration of these cells into a collagen gel
was enhanced when cultured on tenascin-C (Ballard et al.
2006). These data support a role for tenascin-C in the early
stages of angiogenesis by modulating EC adhesiveness,
and thereby to promote migration.
In addition to changes in endothelial-ECM interactions,
a number of humoral mediators, including basic fibroblast
growth factor (bFGF) and vascular endothelial growth
factor A (VEGFA), are required for angiogenesis (Nomi et
al. 2006). Tenascin-C can regulate the EC response to
growth factors as it does for fibroblasts. Resting EC can be
activated by addition of exogenous FBG domain of
tenascin-C in the presence of bFGF (Schenk et al. 1999).
Furthermore, soluble tenascin-C was found to facilitate the
mitogenic response of EC to growth factors such as bFGF.
These effects were mediated by the alternatively spliced
region of tenascin-C (Murphy-Ullrich et al. 1991) (Table 1).
Likewise, enhancement of EC proliferation required a
combination of both bFGF and tenascin-C. This effect
was mediated by binding of the alternatively spliced domains
of tenascin-C to cell-surface annexin II (Chung et al. 1996).
Together, data suggest that modulation of tissue levels of
humoral factors such as VEGFA, regulation of cell response
to key growth factors, and direct effects on cell morphology
and adhesion are mechanisms used by tenascin-C to guide
blood vessel formation during repair.
C. Tissue remodelling
The final stages of tissue repair include differentiation of
fibroblasts into highly contractile α-smooth muscle-rich
myofibroblasts that mediate wound contraction. This
change is followed by cell death by apoptosis and collagen
fibril remodeling (Clark 1993). Tenascin-C expression is
not detected after repair is complete; tenascin-C levels
return to normal after wound contraction and the protein is
not present in scar tissue (Betz et al. 1993; Fassler et al.
1996; Mackie et al. 1988). Tenascin-C mRNA is down-
regulated and the protein is cleared from the tissue
suggesting that it is not likely to play a role in long term
ECM remodeling. However, mice that lack tenascin-C
exhibit delayed infiltration of myofibroblasts upon
myocardial infarction and the alternatively spliced FNIII
repeats and FBG domain stimulated migration, differen-
tiation and collagen gel contraction by cultured cardiac
fibroblasts (Tamaoki et al. 2005). These data suggest that
tenascin-C may promote wound closure at the end of
repair. Conversely, tenascin-C prevents fibroblast contrac-
tion of a 3D fibrin-fibronectin matrix (Midwood and
Schwarzbauer 2002), suggesting that during early repair
stages it may delay contraction as a mechanism of limiting
excessive wound closure until sufficient rebuilding has
occurred. In addition, tenascin-C may modulate cell
apoptosis. Tenascin-C-null mice show earlier mesangial
cell apoptosis than wild-type mice upon kidney injury
(Nakao et al. 1998) and the EGF-L repeats of tenascin-C
are pro-apoptotic when added to cultured smooth muscle
cells (Wallner et al. 2004)( F i g .2).
Summary: tenascin-C in tissue repair
Tenascin-C influences many physiological processes during
tissue repair (Table 2). The pleiotrophic nature of this ECM
molecule was recently highlighted. Using microarray
analysis of gene expression during the repair of striated
leg muscle from wild-type and tenascin-C-null mice, expres-
sion of full length tenascin-C was required for the regulation
of 155 genes that contributed to processes including de-
adhesion, inflammation, angiogenesis, energy metabolism,
fibrinolysis and differentiation (Fluck et al. 2008).
Tenascin-C exhibits archetypal matricellular properties
during the complex progression of events that comprise
tissuerepair(Table2,F i g .2). Whilst little is currently known
of the molecular mechanisms by which tenascin-C affects
the adaptive immune response, its context-specific function
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response via activation of key immune-family receptors and
its anti-adhesive capabilities promote the migration of
keratinocytes, fibroblasts and EC. Competitive binding of
tenascin-C to both ECM proteins and their counterpart cell-
surface receptors mediates its ability to modulate cell-ECM
interactions. The capacity of tenascin-C to interact with a
wide range of ECM molecules may also enable it to
contribute to the structural organization of the ECM. In
addition, tenascin-C can promote migration and proliferation
by direct activation of cell-surface growth factor receptors
and cellular differentiation by up-regulating androgen recep-
tor and EDNRA expression. Tenascin-C also appears to
regulate cellular responses to growth factors on several
levels. It may control tissue levels of growth factors by
regulating their synthesis, by direct binding to increase local
concentrations, or it may affect receptor expression, locali-
zation and clustering. These molecular details remain to be
uncovered, as do the mechanisms by which tenascin-C
mediates apoptosis.
Much of the mechanistic data from the last 5 years has
derived from studies using mice with a targeted disruption
of the tenascin-C gene causing the absence of the tenascin-
C protein in the tenascin-C-null mice. These mice have a
grossly normal phenotype that originally implied a redun-
dancy of tenascin-C. Indeed, recent data have shown that
other ECM proteins exhibit shared functions with tenascin-
C. Fibulin-1 and tenascin-C posses a common mechanism
for modulating fibronectin-syndecan interactions (Williams
and Schwarzbauer 2009), thrombospondin-1 can suppress T
lymphocyte proliferation as effectively as tenascin-C (Puente
Navazo et al. 2001) and osteopontin can substitute for
tenascin-C during vascular remodeling (Cowan et al.
2000). Reduction in fibronectin levels found in suture and
excsional wounds of tenascin-C null mice (Forsberg et al.
1996; Matsuda et al. 1999) present another potential
adaptation mechanism. However, closer inspection of the
response of tenascin-C-null mice to tissue injury has demon-
strated that this matricellular protein is absolutely required
for many aspects of the repair response.
Overview of the role of tenascin-C in tumorigenesis
The tumor microenvironment includes several cell types
besides the cancer cells. Soluble and insoluble factors are
secreted by these cells. But it is still little acknowledged
that the insoluble part of the tumor bed, the “stroma“ (greek
for “mat to lie on“), that is represented by the ECM, is as
instrumental in tumor initiation and cancer progression as
the cells and soluble factors. The tumor ECM isvery complex
and heterogenous amongst different cancer tissues. Moreover
its composition is still poorly understood. The past literature
on the role of tenascin-C in cancer has been extensively
reviewed elsewhere (Chiquet-Ehrismann and Chiquet 2003;
Jones and Jones 2000;O r e n d2005; Orend and Chiquet-
Ehrismann 2006; Vollmer 1997)( F i g .3). Therefore, here we
will focus on more recent data and will only briefly mention
already reviewed data.
Tenascin-C has distinct effects on normal, tumor and
tumor-associated cells based on as yet poorly understood
cell-type specific responses toward this ECM molecule
(Orend and Chiquet-Ehrismann 2000). Tenascin-C is part
of the stroma of most solid cancers, and plays a role in
enhancing proliferation, invasion and angiogenesis during
tumorigenesis and metastasis. Moreover, data support the
possibility that tenascin-C contributes to cancer formation
via its potential interference with genomic stability, by
blocking immunosurveillance, and by providing a favorable
niche for normal and tumor stem cells to survive and
























































Fig. 3 Tenascin-C in cancer
The interaction of tenascin-C
with distinct cell types within a
tumor and the respective cell
responses are shown. Tenascin-
C both inhibits and promotes




induced secretion of pro-
inflammatory cytokines through
binding to TLR4 in rheumathoid
arthritis (Midwood et al.,
2009), it is possible that a
similar mechanism plays a role
in cytokine induction in cancer
metastasis
298 K.S. Midwood, G. Orendexpand. Finally, its high expression correlates with a poor
prognosis for disease-free survival in patients with several
c a n c e r ss u c ha sg l i o m aa n dl u n gc a n c e r( O r e n da n d
Chiquet-Ehrismann 2006), but the molecular basis for
this tumorigenesis-promoting effect of tenascin-C is poorly
understood.
A. Cell adhesion modulation by tenascin-C in cancer
Tenascin-C contains adhesive and anti-adhesive sequences
that coexist in the native molecule. These opposing activities
arise as a consequence of the binding of tenascin-C to ECM
components and cell-surface receptors, and by proteolytic
cleavagereleasingcryptic adhesivesites.One mechanismthat
triggers tenascin-C-specific cell rounding on fibronectin
involves inhibition of syndecan-4 (Huang et al. 2001;
Midwood et al. 2004a). This interference prevents activation
of small GTPase RhoA (Wenk et al. 2000), paxillin and focal
adhesion kinase (FAK) and blocks expression of the actin
stress fiber-stabilizing tumor suppressor-like molecule
tropomyosin-1 in fibroblasts and glioblastoma cells (Lange
et al. 2008). Activation of oncogenic Wnt, EDNRA, and
MAPK signaling, induced by tenascin-C (Ruiz et al. 2004),
and elimination of G1 cell-cycle transition control (Huang et
al. 2001; Orend et al. 2003) could contribute to enhanced
tumor cell proliferation by tenascin-C. The inhibition of
cell proliferation of fibroblasts by tenascin-C might also
have an impact on the function of these cells, since
this inhibition might turn on a secretory program that
potentially transforms a quiescent microenvironment into
a tumorigenesis-stimulating “tumor bed“. For further infor-
mation the reader is referred to Chiquet-Ehrismann and
Chiquet (2003), Orend (2005), Orend and Chiquet-Ehrismann
(2006).
B. Tenascin-C in angiogenesis and matrix tube formation
As mentioned above, tenascin-C is expressed during
formation of new blood vessels in the adult as, e.g. in
granulation tissue of wounds after myocardial infarction, in
arthritis, and in neoplastic diseases. In human gliomas,
tenascin-C expression correlates with the degree of tumor
neovascularization (Herold-Mende et al. 2002). Tenascin-C
may promote angiogenesis through several mechanisms,
such as by serving as a chemoattractant for EC, and by
initiating EC differentiation, survival and proliferation.
These events appear to involve integrin αvβ3, FAK, Prx1
and VEGFA amongst other, not yet identified, molecules
(Orend and Chiquet-Ehrismann 2006). In particular, regula-
tion of VEGFA expression by tenascin-C could be relevant
to tenascin-C-associated tumor angiogenesis, since xeno-
grafted melanoma cells were largely impaired in triggering a
new vasculature in tenascin-C-null mice, which correlated
with reduced VEGFA levels in the circulation (Tanaka et
al. 2004).
In the tissue of malignant melanomas (Kaariainen et al.
2006), breast (Degen et al. 2007) and colorectal carcinomas
(Degen et al. 2008), tenascin-C is frequently not homoge-
nously expressed, but accumulates in matrix tracks. In
search of metastasis-determining factors by differential
expression screening, a combined high expression of
tenascin-C and fibronectin, amongst other factors, turned
out to discriminate between metastatic and non-metastatic
melanomas. Moreover, both molecules were found to
colocalize with laminin and procollagen in tubular channels
that were hollow, contained tumor cells, and were not lined
by blood endothelial or lymph endothelial cells (Kaariainen
et al. 2006). In metastatic breast cancers from MMTV-
VEGF/c-myc transgenic mice, a panel of ECM molecules,
including tenascin-C, several laminins, and collagens were
highly expressed, which was in contrast with non-metastatic
c-myc-induced tumors that displayed largely reduced or no
expression of these molecules (Calvo et al. 2008). It is
intriguing that a combined high expression of distinct
ECM molecules, including tenascin-C and its presentation
in tubular matrix channels, is linked to metastasis.
It is likely that cancer cells use the tenascin-C-containing
matrix tubes to disseminate. This assumption is supported
by data derived from coculture experiments of fibroblasts
together with squamous carcinoma cells (Gaggioli et al.
2007). Fibroblasts scouted their way through matrigel by
degrading the ECM at the front, leaving tubes behind that
they filled with fibronectin and tenascin-C. Subsequently,
the squamous carcinoma cells invaded the matrigel by
using these matrix tubes. The invasive behaviour of the
squamous carcinoma cells was dependent on the fibroblasts
(Gaggioli et al. 2007). A similar observation was originally
made by De Wever et al. (2004) who observed that
carcinoma-associated fibroblasts or fibroblasts that were
“educated“ by TGFβ1 to become myofibroblasts secreted
tenascin-C into the collagen gels, and thus prepared the
ground for colorectal carcinoma cells to be able to invade in
a c-MET- and EGFR-dependent manner. Their invasive
behaviour was due to activation of Rac and the concomitant
inhibition of RhoA (De Wever et al. 2004). Tenascin-C was
instrumental for invasion of the colorectal carcinoma cells
since invasion was inhibited with an anti-tenascin-C
antibody. Tumor-associated macrophages appear to use
collagen tracks within a tumor to guide cancer cells to
blood vessels (Iyengar et al. 2003; Lin et al. 2006; Pollard
2008). Whether these collagen tracks contain tenascin-C
and potentially represent the described matrix tubes is not
known. The existence of vessel-like structures distinct from
blood and lymphatic vessels, linked to metastasis, has been
known for a long time and was coined “vasculogenic
mimicry“ (Hendrix et al. 2003). Whether the observed
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same phenomenon remains to be determined.
In melanomas the tenascin-C-rich matrix tubes were
connected to blood vessels since they contained erythro-
cytes (Kaariainen et al. 2006). Recently, data from Lammert
and colleagues suggest that the evolutionary development
of endothelium-lined blood vessels in vertebrates preceeded
laminin-based matrix tracks in invertebrates (Kucera et al.
2009). In the invertebrate fish amphioxus, laminin filled
tubes are laid down as a scaffold in which a hole is drilled
by cells of unknown origin to generate a coelum that allows
blood to circulate. A similar scenario can be recapitulated in
cocultures of EC with a macrophage cell line, in which the
EC deposited laminin. Subsequently, the macrophages
created a coelum by partially digesting and clearing the
ECM to generate space. The observed tenascin-C matrix
tubes in melanomas and other cancers may offer an
alternative route for dissemination of tumor cells through
their continuum with blood vessels. They also potentially
provide a scaffold to support growth of vessels. This
possibility is interesting considering that the tumor vascu-
lature is mostly distorted and far from providing a
functional circulation system, but nevertheless promotes
cancer cell dissemination. Anti-angiogenic therapeutic
approaches, despite efficient killing of the EC, fail in the
long-run, and even promote tumor progression, which
results in increased and earlier tumor metastasis (Paez-
Ribes et al. 2009; Stockmann et al. 2008). Tenascin-C
matrix tubes would not be affected by anti-angiogenic
drugs. Fusenig and coworkers demonstrated that expression
of tenascin-C in xenografts of squamous carcinoma cells
was unchanged upon elimination of the EC with a VEGFA-
targeting antibody (Vosseler et al. 2005).
Tenascin-C-associated matrix tubes are also present in a
normal setting in so called reticular fibres of secondary
lymphoid tissues. They combine characteristics of basement
membranes and interstitial or fibrillar matrices, resulting in
scaffolds that are strong and flexible, and in certain organs,
such as the thymus, form conduit networks for rapid fluid
transport (Lokmic et al. 2008). In the thymus, the conduits
exhibit a collagen core, a wrapping with laminin and an
outer lining of tenascin-C. In addition, fibrillins 1 and 2
and procollagen II were detected within these conduits
(Drumea-Mirancea et al. 2006). Whether tenascin-C is
required for the formation of the conduits is not known. We
speculate that a program that encodes the establishment of
“thymic conduits“ has been turned on inappropriately in
cancer resulting in the described tenascin-C-containing
matrix tubes. It will be important to understand how these
matrix tubes are created, and which signals induce their
emergence. It will also be necessary to determine what
exact role tenascin-C plays in the formation of the matrix
tubes in the thymus and in cancer.
C. Tenascin-C and mechanical stress
The tenascin-C-rich matrix tubes might also have an impact
on local tissue stiffness, which is an increasingly important
issue in cancer (Boyd et al. 2009). Tenascin-C might affect
tissue resilience and is itself regulated by mechanical stress.
Mechanical stress induced tenascin-C transcription in an
ILK- and MAPK-dependent manner that did not require
protein synthesis. It triggered nuclear translocation of the
SRF (serum response factor) transcriptional coreceptor
MAL (Maier et al. 2008). Conversely, cell adhesion to
composite matrices containing tenascin-C triggered cell
rounding, which could be considered as a relaxed form of
the cell and its actin cytoskeleton. Cell rounding by
tenascin-C was linked to inhibition of membrane recruit-
ment of RhoA (Wenk et al. 2000), reduced RhoA protein
stability, and reduced expression of actin stress fiber-
stabilizing high molecular weight tropomyosins 1 – 3
(Lange et al. 2007). Thus, mechanical stress induces
tenascin-C, tenascin-C may enhance tissue tension and
local stiffness, and cells may counteract this tension
through reduced adhesion (Chiquet et al. 2009).
D. Role of tenascin-C in tumor progression
Multiple oncogenic signaling molecules are induced by
tenascin-C (Ruiz et al. 2004) that potentially are relevant
in tenascin-C-associated metastasis. In particular, a fibronectin/
tenascin-C substratum induceda c t i v a t i o no fW n ts i g n a l -
ing in glioblastoma cells by blocking expression of the
soluble Wnt signaling inhibitor Dickkopf 1 (DKK1) (Ruiz et
al. 2004). There is accumulating evidence for a role of
DKK1 as an instrumental factor in tumor progression by
regulating Wnt signaling in several cell types, which include
tumor cells (Pendas-Franco et al. 2008) and vasculogenic
progenitors (Aicher et al. 2008). Repression of DKK1 may
also be a prerequisite for tumor cells to become responsive to
epithelial-to-mesenchymal transition (EMT)-inducing signals
(DiMeo et al. 2009). Tenascin-C does not only induce Wnt
signaling but is itself also induced by Wnt signaling. In the
lungWnt7binducedtenascin-C(Cohenetal.2009). In another
study it was demonstrated that Wnt signaling transactivated
the tenascin-C promoter in dependence of its TCF binding
sites. This presents an amplification mechanism causing high
tenascin-C expression and persistent Wnt signaling activation.
The potential relevance of this interrelationship between
tenascin-C and Wnt signaling in cancer is supported by the
presence of nuclear β-catenin in human colorectal carcinomas
at the invasive tumor front, where cells are embedded into a
tenascin-C-rich matrix (Beiter et al. 2005).
Tenascin-C induces several molecules that are involved
in EMT. At least six (Wnt, EDNRA, PDGFRα, notch,
TGFβ and EGFR) of the eight pathways that induce EMT
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Tenascin-C may not only activate Wnt signaling but may
also affect TGFβ signaling, since follistatin, a negative
regulator, was repressed by tenascin-C in glioblastoma cells
(Ruiz et al. 2004). Moreover, RNA levels of platelet
derived growth factor α, EDNRA and the notch signaling
target Hes-1 were also increased under the same conditions
(Ruiz et al. 2004). In fibroblasts, tenascin-C activated
EGFR signaling and cell migration through binding of the
EGF-like repeats of tenascin-C to the EGFR (Iyer et al.
2008). In synovial fibroblasts, tenascin-C induced expres-
sion of MMP3 (Tremble et al. 1994). A potential role of
tenascin-C in EMT is also supported by a study in which
MCF7 cells experienced an EMT-like morphological
change on a tenascin-C substratum, that was associated
with induction of the adapter molecule 14-3-3 tau (Martin
et al. 2003). Despite the lack of a formal proof of a causal
role of tenascin-C in full EMT so far, which might be an
issue of appropriate model systems, it is intriguing to notice
that tenascin-C activates multiple oncogenic signaling
molecules and pathways that induce EMT under other
conditions.
E. Role of tenascin-C in metastasis
The first experimental evidence for an instructive role of
tenascin-C in metastasis was recently provided by data
obtained from two murine tumorigenesis models. It was
demonstrated that xenografts of breast carcinoma cells, in
which tenascin-C expression was suppressed by siRNA,
were largely impaired in establishing metastasis in the lung,
which was in contrast with the parental cells that strongly
induced lung metastasis (Calvo et al. 2008; Tavazoie et al.
2008). Tenascin-C was identified as a downstream target of
miR-335 which also regulated expression of the transcrip-
tion factor sox-4 and, suppression of sox-4 in breast cancer
cells by siRNA upregulated tenascin-C expression and lung
metastasis (Tavazoie et al. 2008). Sox-4 was also identified
as target gene to be induced by tenascin-C in glioblastoma
cells (Ruiz et al. 2004), which suggests that expression of
these two molecules could be interdependent and crucial for
metastasis formation.
Summary: tenascin-C in cancer
Tenascin-C performs multiple functions that depend on its
presence as a structural component and on its interactions
with cells by means of specific binding to cell-surface
receptors (Table 3,F i g .3). Many cells interact with
tenascin-C and the resulting responses are context depen-
dent. Tenascin-C activates oncogenic signaling and by that
might promote tumor progression which represents its
signalingnature.Aroleoftenascin-Casarchitectualmolecule
is demonstrated by its interaction with multiple ECM
Table 3 Architectural and signaling functions of tenascin-C
&Architectural function
Conduits in thymus Drumea-Mirancea et al. 2006
Guiding cue for neural crest and neuronal cells Tucker, 2001; Faissner 1997
Release of tissue tension in wound healing Midwood and Schwarzbauer 2002
Matrix with fibronectin Hauzenberger et al. 1999; Chung et al. 1995
Matrix with perlecan Chung and Erickson 1997
Matrix with lecticans Day et al. 2004
Matrix channels in melanomas Kaariainen et al. 2006
&Signaling function
EGFR activation by TN-EGF-L Swindle et al. 2001; Iyer et al. 2007, 2008
Annexin II activation through TNfnIIIA-D Chung and Erickson 1994
Activation of PKC and CaK through contactin binding to TNfnIIID Michele and Faissner 2009
Activation of syndecan-4 through binding to cryptic site in TNfnIIIA2 Saito et al. 2007
Activation of integrin αvβ3, αvβ6, α2β1, α7β1, α8β1, α9β1 see Table 1
Activation of TLR4 through TN-FBG Midwood et al. 2009
Activation of phosphacan/RPTP ζ/β Aukhil et al. 1993
Inhibition of syndecan-4 through competition with fibronectin Huang et al. 2001
Activation of Wnt signaling, repression of DKK1 Ruiz et al. 2004
Induction of endothelin receptor type A Lange et al. 2007
Induction of androgen receptor Ishii et al. 2008
Summary of tenascin-C functions as architectual component of tissues and as inducer of signaling through interaction with transmembrane
receptors and ECM molecules. DKK1, dickkopf 1, CaK, Calcium/calmodulin kinase, PKC, protein kinase C, TLR4, toll like receptor 4
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guiding cues, underneath basement membranes, in reticular
fibers, thymic conduits and in matrix channels of melanomas.
Ectopic expression of tenascin-C in matrix tubes that are
physicallylinkedtobloodvesselsinmetastasticcancersmight
not only have a huge impact on the global mechanical
properties of the tissue, and thereby affect cellular signaling,
but might also function as cues for tumor cell dissemination
and metastasis.
Improved diagnosis and treatment of tenascin-C
associated pathologies
Expression of tenascin-C has already some application in
disease diagnosis. Tissue tenascin-C levels are used as
predictive marker for fibrosis (Lieber et al. 2008; Paivaniemi
et al. 2008) and inflammation in myocarditis (Tsukada et al.
2009), and high tenascin-C serum levels in patients with
inflammatory bowel disease correlate with disease sever-
i t y( R i e d le ta l .2001). Moreover, in breast cancer patients
treated with tamoxifen the high expression of tenascin-C
correlated with a reduced drug responsiveness (Helleman
et al. 2008).
Tenascin-C expression correlates with adverse effects in
pulmonary hypertension, cardiovascular diseases (Fischer
2007), arterial grafting (Sawada et al. 2007), artherioscle-
rosis (Kenji et al. 2004; von Lukowicz et al. 2007), chronic
inflammation and cancer. Inhibition of tenascin-C expres-
sion at the transcriptional level would be the first choice to
prevent tenascin-C actions. Unfortunately, this approach is
not easy to accomplish since many factors and conditions
that trigger tenascin-C expression are not specific for
tenascin-C alone but would affect many other genes with
unwanted side-effects. In cardiovascular diseases, tenascin-
C promotes survival of vascular smooth muscle cells and
hyperproliferation which is linked to heart failure (Hedin et
al. 1991; Jones et al. 1997; Milting et al. 2008). Inhibition
of phosphodiesterase III by cilostazol may present a
suitable approach since this drug reduces tenascin-C
expression in vascular smooth muscle cells and prevents
neointimal hyperplasia (Fujinaga et al. 2004; Yamamoto et
al. 2007). Inhibition of angiotensin II, which is a potent
inducer of tenascin-C, with drugs such as angiotensin II
type 1 receptor (AT-1) antagonists and angiotensin convert-
ing enzyme (ACE) inhibitors potentially present another
means to block vascular tenascin-C expression in hyper-
tensive patients (Fischer 2007). In a glioblastoma patient
double stranded anti-tenascin-C RNA was used to reduce
tenascin-C expression (Zukiel et al. 2006). Tenascin-C
expression was also shown to be blocked with a tenascin-C
specific antisense/ribozyme, which prevented progression
of the vascular disease (Cowan et al. 2000).
More mechanistic insight into tenascin-C actions in
diseased tissues could provide information that may be
useful in disease treatment. In this sense it needs to be
determined whether blocking TLR4 in rheumatoid arthritis
and cancer, and restoration of syndecan-4 function, or
blocking tenascin-C-induced oncogenic signaling in tumors
are suitable strategies to counteract tenascin-C and poten-
tially ameliorate or erradicate the pathological situation.
Given its high expression in diseased tissues, a promis-
ing approach is the targeting of tenascin-C with anti-
tenascin-C-directed antibodies coupled to cytotoxic agents.
A bispecific CD95/anti-tenascin-C antibody that activated
the Fas/Apo-1 death receptor efficiently caused glioma cell
lysis that was strongly enhanced in combination with
topoisomerase inhibitors or doxorubicin (Herrmann et al.
2008). Similarly, recruitment of the immune system by
attaching IL2 to an anti-tenascin-C antibody (G11) (Marlind
et al. 2008) or coupling cytotoxic radioactivity to the B8C6
anti-tenascin-C antibody represent other potentially efficient
strategies (Reardon et al. 2008). DNA based aptamers that
specifically recognize tenascin-C may also be suited for
targeting tenascin-C (Hicke et al. 2006). Tenascin-C target-
ing antibodies are in advanced clinical trials for use in tumor
imaging and therapy (Akabani et al. 2005; Silacci et al.
2006). These applications would require high amounts of
tenascin-C specific antibodies which could be achieved
by expression of a single chain antibody that recognizes
human tenascin-C in the plant nicotiana bentamiana
(Villani et al. 2009).
Parallels between tenascin-C-associated inflammation,
the repair process and tumorigenesis
Clinical and epidemiologic studies suggest a strong asso-
ciation between inflammation and cancer (Coussens and
Werb 2002; Hussain et al. 2003; Lin and Karin 2007;
Shacter and Weitzman 2002). Inflammation appears to
orchestrate the tumor microenvironment and is a critical
condition for both tumor promotion and tumor progression
(Balkwill et al. 2005). The inflammatory milieu of tumors
is characterized by cells such as resident and recruited
macrophages, dendritic cells, T cells and NK cells (Luster
et al. 2005). These infiltrated immune cells can produce
pro-inflammatory mediators that weaken anti-tumor immu-
nity (Ben-Baruch 2006; Smyth et al. 2004). Most pro-
inflammatory cytokines (e.g. IL6, IL8, TNFα) produced by
either host immune cells or tumor cells can themselves
promote tumor development. By contrast, pro-apoptotic
(e.g. TRAIL) and anti-inflammatory (e.g. IL10) cytokines
usually interfere with tumor development (Lin and Karin
2007). A persistent inflammatory microenvironment can
induce tumor promotion, and accelerate tumor progression,
302 K.S. Midwood, G. Orendinvasion, angiognesesis and often metastasis (Coussens and
Werb 2002; Dobrovolskaia and Kozlov 2005; Karin and
Greten 2005).
Activation of TLR signaling presents a mechanistic link
between inflammation and cancer. TLR signaling can
enhance tumor development by means of various mecha-
nisms. In a mouse model of transplanted metastatic cancer
cells, activation of TLR4 by intraperitoneal injection of
bacterial LPS stimulated the growth of lung metastasis,
which was linked to the production of several different
inflammatory cytokines (Harmey et al. 2002; Luo et al.
2004; Pidgeon et al. 1999). In this scenario activation of
TLR4 by tenascin-C might play a similarly important role.
Tenascin-C maintained chronic inflammation in rheumatoid
arthritic joints through binding and activation of TLR4,
which subsequently stimulated secretion of pro-inflammatory
cytokines IL6, IL8 and TNFα (Midwood et al. 2009).
Whether TLR4 activation by tenascin-C promotes tumor
progression is an intriguing possibility that needs to be
addressed in the future. Other ECM molecules such as
biglycan and versican also activated TLRs, with biglycan
binding to TLR2 and TLR4 (Schaefer et al. 2005), and
versican binding to TLR2 (Kim et al. 2009). Activation of
TLR2 by versican in myeloid cells induced secretion of
TNFα and IL6, which caused metastatic spread of murine
LLC lung carcinoma cells to the lung (Kim et al. 2009).
These data suggest that activation of TLRs by soluble
and insoluble ECM ligands can induce secretion of pro-
inflammatory cytokines that would promote tumor progres-
sion and metastasis (Table 2).
An extensive literature supports similarities between
wound healing and cancer. Tumors are even considered as
wounds that exhibit an abnormal healing process (Schafer
and Werner 2008). Several components of the tumor stroma
are common to those of the granulation tissue in healing
skin wounds, which suggests that epithelial tumors poten-
tially promote the formation of their stroma by activating
the wound-healing response of the host. However, in
contrast to healing wounds, the process is not self-limiting
in cancer tissue, and this leads to uncontrolled cell prolifer-
ation, invasion and metastasis. In particular, a matrix of
crosslinked fibrin and fibronectin containing tenascin-C is
present during wound healing (Midwood et al. 2004b), and
ectopic expression of fibronectin, fibrin and tenascin-C is a
hallmark of cancer (Kaspar et al. 2006; Konstantopoulos and
Thomas 2009;M c M a h o na n dK w a a n2008; Orend and
Chiquet-Ehrismann 2006; Rybak et al. 2007). Wound
healing and tumor vessels are initially immature and leaky,
and VEGFA controls angiogenesis in wounds and tumors.
Tenascin-C regulates VEGFA levels by an unknown mecha-
nism (Tanaka et al. 2004), and suture wounds in skin and
retina heal poorly in tenascin-C-null mice (Forsberg et al.
1996; Matsuda et al. 1999). Wound re-epithelialization is an
event that is reminiscent of EMT, which is also a hallmark of
cancer. Tenascin-C might be involved in EMT in both
wounds and tumors, since tenascin-C not only induces EMT-
like morphologically changes in culture, and induces genes
that trigger EMT, but is also expressed in wounds and cancer
tissue at sites, where EMT occurs.
Our increasing insight into the mechanisms involved in
the functions of tenascin-C combined with the existing
strategies for targeting this protein, generate optimism that
some life-threatening and painful diseases in which tenascin-
C is highly expressed will be better managed in the not so
distant futurebyapplyingthisknowledge for treatment and/or
diagnosis.
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